In aggregate, these observations support the consideration of CS hemoadsorption in the management of severe rhabdomyolysis, particularly in patients with very high myoglobin levels (>10,000 μg/L) who are at imminent risk or already have evidence of AKI. This evidence concerns the gene MB and rhabdomyolysis.